Biotech stock trader april 2012


Published on

Cytomedix Stands Taller than Competition with New Treatment for Diabetic Foot Ulcers and More

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Biotech stock trader april 2012

  1. 1. April 16, 2012Cytomedix Stands Taller than Competition with NewTreatment for Diabetic Foot Ulcers and MoreThe biotechnology industry is thriving and one of the fastest growing markets available forinvestment today. Within the industry, the diabetes sector is outpacing most others. In lateFebruary, leading business intelligence provider GBI Research released its DiabetesTherapeutics Market to 2017 report. The analysis detailed why the firm sees the global diabetestherapeutic industry growing from $29.3 billion 2010 at a compound annual growth rate of 7.1percent to $47.2 billion in 2017. While many investors seem to think that the most lucrativeinvestments are in traditional drugs like Novo Nordisk AS s (NYSE: NVO) Victoza, Merck & Co. s(NYSE: MRK) Januvia or the highly touted new blood-sugar-lowering drug, dapagliflozin, fromBristol-Myers Squibb Co. (NYSE: BMY) and AstraZeneca PLC (NYSE: AZN), the diabetes spacegenerates billions annually related to some serious complications associated with the dreadeddisease. As such, the upside to many smaller companies, such as Cytomedix, Inc. (OTCBB:CMXI), that are poised for rapid growth in the diabetes space with their new technologiesshould not be overlooked.Diabetic foot ulcers (DFUs) are the most common foot injuries leading to lower extremityamputation, occurring in 15 percent of patients with diabetes and preceding 84 percent of alllower leg amputations. Globally, 366 million people currently have diabetes with that numberexpected to mushroom to more than 550 million (10% of the world s population) by 2030,according to the International Diabetes Federation. At a 15% clip, that will put the number ofpeople suffering from the ulcers at more than 20 million. The vast majority of diabetic footcomplications resulting in amputation begin with the formation of skin ulcers. In these cases itis difficult to repair and rebuild the lost extracellular matrix (ECM) because diabetes mellitus is ametabolic disorder that impedes normal healing that would be seen in a non-diabetes patient.This is where Cytomedix, a leader in the commercialization of innovative autologous therapiesthat promote healing by harnessing the innate regenerative capacity of platelets and adult stemcells, offers a revolutionary technology that outstrips current wound care therapies andprovides a convenient and cost-effective new approach.The company s PRP (Platelet Rich Plasma)-based AutoloGel System revitalizes a patient snatural healing processes by delivering a topical gel containing growth factors, cytokines andchemokines for cell growth and formation of new tissue. According to the Cytomedix website,
  2. 2. By delivering both fibrin matrix and platelet releasate to the chronic wound bed, the AutoloGelSystem re-establishes the natural balance the body needs to escape the inflammatory phase sorestoring the natural healing process.A prospective, randomized, controlled trial sponsored by Cytomedix demonstrated both safetyand efficacy of AutoloGel with 81.3% of wounds in the majority DFU wound size group fullyhealing as compared to 42.1% in the control group which received a saline gel therapy.Additional positive data on the AutoloGel System was recently published in a feature article inthe April 2012 issue of Ostomy Wound Management showing that in 39 limb salvage patients inJapan, 83% of the wounds progressed to complete healing in an average of 145.2 days(p=0.00002) using an average of 6.1 AutoloGel treatments.Importantly, Cytomedix is awaiting a May 9, 2012 decision from the Centers for Medicare &Medicaid Services (CMS) on reimbursement coverage of the AutoloGel System. Medicarecovers nearly 11 million people with diabetes currently and, traditionally, private insurers willfollow the path set forth by CMS in supporting insured treatments. With approximately 26million diabetes patients diagnosed in the U.S., sales could catapult ahead for Cytomedix if CMSbegins covering AutoloGel.Clearly, the diabetes population alone could provide a solid backbone for exponential growthfor Cytomedix, but it is only a portion of what the company has to offer. For brevity s sake, thisarticle has only focused on the massive potential of AutoloGel in the diabetes arena.Cytomedix s PRP technology has multiple uses in wound therapy outside of just DFUs and thecompany s portfolio covers a wide array of regenerative therapies that are already generatingmeaningful revenue. The company has recently completed the acquisition of Aldagen and theirrobust and differentiated pipeline of regenerative cell therapies. The newly acquired ALDHBright Cell technology has been shown to be a marker of a cell s ability to grow. In otherwords, it can differentiate, identify and measure the vitality of cells to determine which arehighly metabolic to facilitate the growth of new tissue.Regenerative medicine has become a busy space with numerous companies looking to answerthe question, What is going to be the best therapy across several applications? With its widespectrum covering wound therapy, angiogenesis (which can be used for several types ofischemia and multiple other indications) and inflammation treatments, Cytomedix is answeringthat question. It s uniquely positioned and stands head-and-shoulders above most other OTCbiotechnology companies as it already has commercial products in the marketplace generatingrevenues as it relentlessly pursues advancement of its other proprietary products.For more information, please see the following resources: · Company Website · Recent SEC Filings